This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
1sbg
From Proteopedia
OCA (Talk | contribs)
(New page: 200px<br /> <applet load="1sbg" size="450" color="white" frame="true" align="right" spinBox="true" caption="1sbg, resolution 2.3Å" /> '''AN ORALLY-BIOAVAILAB...)
Next diff →
Revision as of 12:22, 8 November 2007
|
AN ORALLY-BIOAVAILABLE HIV-1 PROTEASE INHIBITOR CONTAINING AN IMIDAZOLE-DERIVED PEPTIDE BOND REPLACEMENT. CRYSTALLOGRAPHIC AND PHARMACOKINETIC ANALYSIS
Overview
(2R,4S,5S,1'S)-2-Phenylmethyl-4-hydroxy-5-(tert-butoxycarbonyl), amino-6-phenylhexanoyl-N-(1'-imidazo-2-yl)-2'-methylpropanamide (compound, 2) is a tripeptide analogue inhibitor of HIV-1 protease in which a, C-terminal imidazole substituent constitutes an isoelectronic, structural, mimic of a carboxamide group. Compound 2 is a potent inhibitor of the, protease (K(i) = 18 nM) and inhibits HIV-1 acute infectivity of CD4+, T-lymphocytes (IC50 = 570 nM). Crystallographic analysis of an HIV-1, protease-compound 2 complex demonstrates that the nitrogen atoms of the, imidazole ring assume the same hydrogen-bonding interactions with the, protease as amide linkages in other peptide analogue inhibitors. The sole, substitution of the C-terminal carboxamide of a hydroxyethylene-containing, tripeptide analogue with an imidazole group imparts greatly improved, pharmacokinetic and oral bioavailability properties on the compound, compared to its carboxamide-containing homologue (compound 1). While the, oral bioavailability of compound 1 in rats was negligible, compound 2, displayed oral bioavailabilities of 30% and 14%, respectively, in rats and, monkeys.
About this Structure
1SBG is a Single protein structure of sequence from Human immunodeficiency virus type 1 (isolate bh10) with IM1 as ligand. Full crystallographic information is available from OCA.
Reference
An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: crystallographic and pharmacokinetic analysis., Abdel-Meguid SS, Metcalf BW, Carr TJ, Demarsh P, DesJarlais RL, Fisher S, Green DW, Ivanoff L, Lambert DM, Murthy KH, et al., Biochemistry. 1994 Oct 4;33(39):11671-7. PMID:7918383
Page seeded by OCA on Thu Nov 8 14:28:24 2007
